Stem cell treatment for acute myocardial infarction

Area of Science:

• Cardiology
• Regenerative Medicine
• Stem Cell Biology

Background:

• Stem cell therapy shows promise for regenerating cardiac tissue post-acute myocardial infarction (AMI).
• Numerous randomized controlled trials (RCTs) have investigated this therapeutic approach worldwide.

Purpose of the Study:

• To critically evaluate the evidence from RCTs on the effectiveness of adult bone marrow-derived stem cells (BMSC) for treating AMI.
• This review is an update of a previous Cochrane review published in 2008.

Main Methods:

• Searched multiple databases (MEDLINE, EMBASE, CENTRAL, CINAHL, Transfusion Evidence Library) up to January 2011.
• Included RCTs comparing autologous stem/progenitor cells versus no cells in AMI patients.
• Independent data extraction and quality assessment by two authors; random-effects meta-analysis with heterogeneity exploration.

Main Results:

• Thirty-three RCTs (1765 participants) were included. BMSC treatment did not significantly alter mortality or morbidity rates.
• A significant, sustained improvement in left ventricular ejection fraction (LVEF) was observed, both short-term and long-term (up to 61 months).
• Reduced left ventricular volumes and infarct size were noted long-term; correlations found between cell dose/timing and LVEF improvements.

Conclusions:

• Despite heterogeneity, BMSC therapy offers moderate, sustained improvements in global heart function post-AMI.
• Larger trials are needed to assess clinical effects due to low event rates.
• Standardization of methodology, cell dosing, timing, and patient selection is crucial to reduce heterogeneity.